

Available online at www.sciencerepository.org

# **Science Repository**



# **Research Article**

# F-FDG Uptake Is Predictive of Poor Survival After Surgery for Large-Cell-Neuroendocrine-Carcinomas of The Lung: A Bicentric Analysis

Filippo Lococo<sup>1#</sup>, Ludovic Fournel<sup>2\*#</sup>, Maria Cecilia Mengoli<sup>3</sup>, Angelina Filice<sup>4</sup>, Cristian Rapicetta<sup>1</sup>, Audrey Lupo<sup>5</sup>, Teresa Di Stefano<sup>1</sup>, Aurélie Janet-Vendroux<sup>2</sup>, Massimiliano Paci<sup>1</sup> and Marco Alifano<sup>2</sup>

<sup>1</sup>Unit of Thoracic Surgery, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Italy.

<sup>2</sup>Unit of Thoracic Surgery, Cochin Hospital, Paris-Center University hospitals, AP-HP, Paris Descartes University, Paris, France.

<sup>3</sup>Unit of Pathology, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Italy.

<sup>4</sup>Unit of Nuclear Medicine, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Italy.

<sup>5</sup>Unit of Pathology, Cochin Hospital, Paris-Center University hospitals, AP-HP, Paris Descartes University, Paris, France.

#Equally contributed to this paper

# ARTICLEINFO

Article history: Received: 23 June, 2019 Accepted: 8 July, 2019 Published: 30 August, 2019 Keywords: large cell neuroendocrine carcinoma F-FDG survival lung cancer

# $A\,B\,S\,T\,R\,A\,C\,T$

**Introduction:** Large cell neuroendocrine carcinoma (LCNEC) represents a relatively rare and poorly studied entity whose management is not clearly established. The aim of this study was to explore the relationship between preoperative <sup>18</sup>F-FDG-PET results, pathological features and long-term survival in a large surgical cohort of LCNEC.

**Methods:** From 06/08 to 06/17, the clinical, radiometabolic, pathological and surgical aspects of 121 LCNEC-patients surgically treated in 2 tertiary centers were retrieved. A Cox regression model was used to identify predictors of survival and Kaplan-Meier method to summarize overall survivals.

**Results:** Mean age and male/female ratio were  $63.4\pm8.3$  and 3:1, respectively. The main clinical, radiometabolic and surgical characteristics are reported in Tab.1. Most patients were active/former smokers and presented symptoms at diagnosis. <sup>18</sup>FDG-PET/Scan was performed in 65 patients (53.7%) with a mean SUVmax of 10.1 (SD±4.6). Higher SUVmax values (SUVmax >10) were detected in tumors with larger size (p=0.004), advanced p-Stages (p=0.019), presenting necrosis (p=0.077) and with positive staining for CD56 (p=0.025) and TTF-1 (0.063). After surgery (R0 in 91% of cases), 52 (43%) patients had pStage-I while about 35% of patients presented with N1-2 disease. Median, 3-yrs and 5-yrs overall survival was 40 months, 52.2% and 44.6%, respectively. At univariate analysis, the survival was significantly influenced by SUVmax values (p=0.009) and by the presence of vascular invasion at pathological examination (p=0.024). Multivariate analysis showed as the FDG-SUVmax was the only independent variable affecting long-term survival (HR:2.86;C.E.: 1.09-7.47;p=0.032).

**Conclusions:** Patients underwent surgical resection for LCNEC of the lung experienced a poor prognosis (5-yrs survival = 44.6% in this study). High-level FDG accumulation (SUVmax >10) correlates with pathological features and results to be independently predictive of poor survival after surgery. This parameter should be taking into account when planning the best strategy of care.

© 2019 Ludovic Fournel. Hosting by Science Repository.

<sup>\*</sup>Correspondence to: Dr. Ludovic Fournel, Thoracic surgery department, Cochin Hospital, Paris center university hospital, APHP, University of Paris, 27 rue du faubourg Saint-Jacques, 75014, Paris, France; Tel: +33 1 58 41 42 41, Fax: +33 1 58 41 20 74; E-Mail: ludovic.fournel@aphp.fr

<sup>© 2019</sup> Ludovic Fournel. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository. http://dx.doi.org/10.31487/j.JSO.2019.03.01

Among lung cancers, large cell neuroendocrine carcinoma (LCNEC) represents a relatively rare entity whose ideal management is not clearly established yet. These poorly-differentiated neuroendocrine tumors (NETs), previously classified as "high grade" malignancies in contrast to low grade NETs (carcinoids), are composed of large cells but sometimes exhibit molecular signature of small cell lung carcinoma (SCLC) [1]. They usually are associated with a poor prognosis even if a combined approach consisting in tumor resection and appropriate systemic treatment could improve survival as reported in surgical series

Table 1: Clinical, Radiological and Pathological Features of the Population

of the last-decade, leading to oncological results close to those of other operated non-small cell lung carcinomas (NSCLC) [2-5]. However, the identification of preoperative prognostic factor in order to clarify surgical eligibility criteria as well as to define adjuvant treatment indications remains one of the major challenges in the multimodal management of this uncommon entity [6,7]. In this setting, the role of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography (<sup>18</sup>F-FDG-PET) in predicting pathological features and long-term survival is still undefined. The aim of this study was to explore the relationship between preoperative <sup>18</sup>F-FDG-PET results, pathological features and long-term survival in a large surgical cohort of LCNEC.

Table 1. Chineai, Nationogical and Tationogical Teatures of the Topulation	
Variable	Value
Population, n	121
Age Mean, SD	74.9±10.6
Sex n, %	
Male	90 (74.4)
Female	31 (25.6)
Smoking History n, %	
Y	109 (90.1)
N	12 (9.9)
Paraneoplastic Syndrome n, %	
Y	7 (5.8)
N	114 (94.2)
Symptoms at Presentation n,%	
Y	72 (59.5)
Ν	49 (40.5)
<sup>18</sup> FDG-PET/Scan n, %	
Y	65 (53.7)
N	56 (46.3)
Intervention Type n, %	
Pneumectomy	13 (10.7)
Bilobectomy	2 (1.7)
Lobectomy	86 (71.0)
Sleeve-Lobectomy	3 (2.4)
Typical Segmentectomy	7 (5.8)
Wedge Resection	5 (4.1)
Exploratory thoracotomy	5 (4.1)
pT n, %	
1	52 (43.0)
2	40 (33.1)
3	18 (14.9)
4	11 (9.1)
pN n, %^	
0	78 (64.4)
1	16 (13.2)
2	27 (22.3)
pSTAGE	
IA	38 (31.5)
IB	14 (11.6)
IIA	9 (7.4)
IIB	18 (14.9)
IIIA	24 (19.8)
IIIB	9 (7.4)
IVA	9 (7.4)
Tumor Size Mean (cm)	33

Resection Status n, %	
R0	110 (90.9)
R1	11 (9.1)
(Neo)CHT n, %^	
Y	55 (45.5)
Ν	66 (54.5)
Radiotherapy n, %^	
Y	25 (20.6)
Ν	96 (79.8)

^ missing data

#### **Materials and Methods**

From June 2008 to June 2017, the clinical, radiometabolic, pathological and surgical aspects of 121 consecutive LCNEC-patients treated in 2 tertiary centers were retrospectively reviewed. Patients without pathological confirmation based on histology were excluded from the analysis. The Promoting Center (IRCCS-Arcispedale Santa Maria Nuova-Reggio Emilia) selected the other institution considering its highvolume and certain homogeneity of treatment that substantially agreed on the "management policy "of this pathology. Before undertaking our data analysis, IRB approval (Protocol\_Number: 2018/0075167) was obtained for the research use of retrospectively collected data (observational) stemming from standard clinical practice. Data related to age, gender, smoking history, radiological and radiometabolic evaluation, TNM status, type of treatment, surgical notes and pathological/immunohistochemical features were reviewed and recorded (Table 1).

#### I Diagnostic work-up

Despite minimal differences between centers, the pre-operative work up examination was essentially the same, this resulting substantially the same performed in NSCLC-patients and reported in [8]. <sup>18</sup>F-FDG-PET/CT-scan was performed in the majority of the cases (65 of 121, 53.7%), according to local practices and especially when radiometabolic results could be useful in the multisciplinary evaluation of a multimodal approach.

#### **II Surgical Technique and Pathological Evaluation**

Despite some unavoidable variability in the surgical technique among the two centers involved, the surgical policy adopted when planning the pulmonary resection extension was based on similar assumptions as indicated below:

- parenchymal resection to a lesser extent than a lobectomy was considered oncologically inappropriate and was never performed in "clinically fit" patients;
- sub-lobar resection (segmentectomy or wedge resection) was indicated only in patients judged "clinically unfit" for lobar resection;
- 3) lymph node dissection (lobe-specific or complete) was performed in all cases, and the mediastinal tissue encompassing the lymph nodes was dissected and removed systematically within typical anatomical landmarks.

Surgical-pathological stage was (re)assigned according to the 7<sup>th</sup>TNM classification system and the resection was considered complete (R0) according to the criteria purposed by the International Association for the Study of Lung Cancer Staging Committee and data from patients observed and treated before its introduction into clinical practice have been updated to cohere with this classification system and to obtain homogeneous staging information throughout the entire cohort [9]. A centralized blind pathological revision of the samples was performed by an expert pathologist specializing in lung pathology (M.M.) to avoid any variations in the pathological diagnosis and to achieve substantial concordance with the histopathological characteristics of the samples evaluated. The revision was performed according to the revised 2015 World Health Organization classification for LCNEC on which the following diagnostic criteria are based [10].

Based on histological features of neuroendocrine morphology including rosettes and peripheral palisading patterns, neuroendocrine features were confirmed by immunohistochemistry (IHC) expression of at least one neuroendocrine marker (synaptophysin [SYN], chromogranin-A [CGA], and CD56). Notably, enrolled samples included histologically mixed LCNEC (tumors with morphologically identifiable ADC or SQCC component) where included only when LCNEC presented as the dominant type ≥90%. Representative paraffin blocks were selected on base of H&E staining. Three-µm thick FFPE slides were stained using a Leica BOND Autostainer according to the manufacturer's instructions. Tissue sections were analyzed by immunohistochemistry with following primary antibodies: TTF-1 (1:200, mouse monoclonal, clone: 8G7G3/1; Dako, Danmark), Ki67 (1:150, mouse monoclonal; clone MIB1; Dako Danmark), CD56 (1:100, mouse monoclonal, clone:123C3; Dako, Danmark), Synaptophysin(1:50, mouse monoclonal, clone:DAK-SYNAP, Dako, Danmark), chromogranin A (1:200, mouse monoclonal, clone:DAK-A3, Dako, Danmark).

### III Postoperative treatment and follow-up

Adjuvant platinum-based chemotherapy and/or radiotherapy were given under the care of referring oncologists. The clinical records from outpatient clinics and correspondence with the patient's referring physician provided information on the health status of the patient. Follow-up data were available for all of the patients.

### **IV Statistical Analysis**

Categorical variables were compared using Fisher's exact test or Chisquare test, and continuous variables were compared using the Mann– Whitney U test. Overall survival (OS) was defined as the period from the date of resection or biopsy to the date of death. Since there were no post-operative data regards of 10 patients, OS analysis was performed on 111 LCNEC cases. Patients who were alive at the time of last follow-up were censored.

OS was analyzed by the Kaplan-Meier plots and the log-rank test was used to calculate the significance between groups. The prognostic factors for OS were analyzed using univariate and multivariate COX proportional hazard model. The two-sided significance level was set at p < 0.05. Data were analyzed using the Statistical Package for the Social Sciences Version 23.0 Software (SPSS, Inc., Chicago, IL) and the survival curve was drawn with GraphPad Prism 5.01 (GraphPad Software, San Diego, CA).

# Results

The main clinical, radiometabolic, surgical and pathological features are summarized in (Table 1). Mean age and male/female ratio were 63.4±8.3

Table 2: Correlation between <sup>18</sup>FDG-SUVMax-T and pathological features

and 3:1, respectively. Most patients (about 90%) were active/former smokers and presented with symptoms at diagnosis (more than 50%). Lobectomy was the most common surgical procedure (~70%) followed by pneumonectomy and anatomical segmentectomy. Extended resection to adjacent organs (chest wall in 19 cases, pericardium in 4, and diaphragm in 2) was performed in 25 (20.6%) cases and radical resection was achieved in more than 90% of cases despite 5 explorative thoracotomies. At pathological stage, about 2/3 of patients had a T1-T2 tumors while a N1/N2 involvement was found in about 35% of patients (Table 1). At microscopic evaluation, the number of mitoses was high (> 2/10 HPF) in most part of surgical specimens with more than 80% of them showing areas of necrosis. At immunohistochemical staining (data not shown), surgical specimens were positive for CgA in 83.5% and for TTF-1 in 67.7% of cases. Chemotherapy was administered before or after surgery in about half of cases while post-operative radiotherapy was indicated and performed in 20% of them.

Variables		#pts	SUVMax Mean	р
Tumor-Size	≤3.3	34	8.0	0.004
	>3.3	31	11.2	
рТ	>2	38	10.9	0.004
	≤2	27	7.7	
pN	$\geq l$	21	10.5	0.359
	$\leq l$	44	9.4	
p-Stage Group	$\geq 2$	36	11.3	0.019
	<2	29	8.6	
Vascular Invasion^	Y	31	10.0	0.523
	Ν	17	9.2	
Mitosis N	<2/10HPF	8	7.7	0.203
	>2/10HPF	57	10.5	
Necrosis	Y	57	10.5	0.077
	Ν	8	6.3	
CD56^	Р	23	9.8	0.025
	Ν	4	15.3	
CgA^	Р	45	10.0	0.603
	Ν	12	10.8	
TTF1^	P	40	9.5	0.063
	N	12	11.8	
Ki67(%)^	≥50%	30	12.8	0.05
	<50%	22	8.8	

^missing data

# I Inter-relationship between Radiometabolic Results and Pathological features

<sup>18</sup>FDG-PET/Scan was performed in 65 patients (53.7%) with a mean SUVmax of 10.1 (SD±4.6). When correlating the radiometabolic results (SUVmax values) with pathological features (Table 2), the Chi-squared test revealed as higher SUVmax values were detected in tumors with larger ( $\geq$ -3cm) size (SUVmax: 11.2 vs 8, p=0.004), advanced (I vs II-IV) Stages (SUVmax: 11.3 vs 8.6, p=0.019), presenting high levels (>50%) of ki-67 (SUVmax: 12.8 vs 8.8, p=0.05) or necrosis (SUVmax: 10.5 vs 6.3, p=0.077) at pathological evaluation. No significant association was observed according to N-status and presence of vascular invasion at specimen evaluation. Moreover, we observed a similar correlation between SUVmax values and negative staining for CD56 (p=0.025) and (borderline) TTF-1 (0.063).

#### **II Survival Results**

Median, 3-yrs and 5-yrs overall survival was 40 months, 52.2% and 44.6%, respectively (Fig.1A), with a mean follow-up of 71 months (range 11–103 months). At univariate analysis performed on 111 patients (Tab.3), we observed a trend of association between the long-term survival and pStage with 5-yrs survival of 53.8% in pStage-I vs 35.9% in pStage II/III/IV (p=0.06, Fig. 1B). A stronger association was found exploring long-term survival and the presence of vascular invasion at pathological examination (61.0% vs 33.5%, p=0.024; Fig. 1C) and even more SUVmax values (p=0.009; Fig. 1D). No other prognostic factors were observed (Table 3). Multivariable analysis showed as the FDG-SUVmax was the only independent variable affecting long-term survival (HR:2.86;C.E.: 1.09-7.47;p=0.032).



Figure 1: Kaplan-Meyer Survival Curves of the overall population (A), according to SUVmax values (B), pStage (C) and the presence of vascular emboli (D).

# Table 3: Survival results: univariate analysis

OS         111         44.5         40         22.58         .           Gender         Male         85         48.9         44         14.74         0.095           Fende         26         27.6         29         5.53         .           Smoking History         .         .         .         .         .           Y         7         51.4         .         .         .           PEDC PET         .         .         .         .         .           Y         57         46.5         50         26.74         0.296           N         51         41.9         30         9.51         .           %TO StroMas (Cathegorical)         .         .         .         .         .           *A7         34         65.5         .         .         .         .         .           *A7         34         65.5         .         .         .         .         .         .           247         34         65.5         .         .         .         .         .           470         51         58         55.7         .         .         .         . </th <th></th> <th># pt</th> <th>% 5y</th> <th>Median (months)</th> <th>Conf.</th> <th>p Value</th>		# pt	% 5y	Median (months)	Conf.	p Value
Os         111         44.5         40         22.58         .           Make         85         48.9         44         14.74         0.055           Famale         85         48.9         44         14.74         0.055           Smoking Illitory         94         46.2         44         14.74         0.459           N         7         51.4         .         .         .           "FDG PET         7         46.5         50         26.74         0.296           N         54         41.9         30         9-51         .           "FDG FET         7         46.5         50         26.74         0.296           N         54         41.9         30         9-51         .           *9.7         28         23.2         29         14.44         0.009           Tumor Size (Cathegorical)	00		11.6	10	iterval (95%)	
Ormer         Mate         85         48.9         44         14-74         0.195           Fende         26         27.6         29         5-53           Smoking Ilistory         -         -         -           Y         57         51.4         .         .           PEOG PET         -         -         .           Y         57         46.5         50         26-74         0.296           N         54         41.9         30         9-71         0.296           MPC StorMax (Cathegorical)         -         -         -         -           *77         28         23.2         29         14-44         0.009           Tumor Size (Cathegorical)         -         -         -         -         -           *4.7         53         39.5         33         10-56         -         -           PT         -	US G	111	44.6	40	22-58	-
Mute         85         48.9         44         14-44         0.05           Penule         26         27.6         29         5.53           Smoking History         7         51.4         .         .           "FDG PET         7         51.4         .         .           "FDG Str         7         51.4         .         .           "FDG Str         7         46.5         50         26.74         0.296           N         54         41.9         30         9-51         .           *PTG SurvMax (Cathegorical)         .         .         .         .         .           *9.7         28         25.2         .         1.4-44         0.009           Tumor Size (Cathegorical)         .         .         .         .         .           <4.3         58         55.7         65         39-91         0.104           >3.3         30.5         33         10.56         .         .           PT         .         .         .         .         .           4.3         51         58.4         92         38.146         0.136           2         .         <	Gender	0.5	10.0		14.74	0.105
Penular         26         27.6         29         5-33           Smoking History         94         46.2         44         14-74         0.459           N         7         51.4         .         .         .           "FDG PET         7         51.4         .         .         .           "FDG StorMax (Cathegorical)         .         .         .         .         .           *07         34         65.5         .         .         .         .           *07         34         65.5         .         .         .         .           *07         28         23.2         29         14-44         0.009           Tumor Size (Cathegorical)         .         .         .         .         .           <3.3         53         39.5         33         10-56         .           pT         .         .         .         .         .         .           J         51         58.4         92         38.440         0.126           P         .         .         .         .         .         .           J         1.6         .         .         .	Male	85	48.9	44	14-74	0.195
Snoking Ilistory         Y         94         46.2         44         1.474         0.459           Y         7         51.4         .         .         .           "FDG PET         7         46.5         50         26.74         0.296           N         54         41.9         30         9.51         .           "FDG SurvMax (Cathegorical)         .         .         .         .           40.7         28         23.2         29         14.44         0.009           Tumor Size (Cathegorical)         .         .         .         .         .           4.3.3         58         55.7         65         39.91         0.104           2.3.3         53         33         10.56         .         .           97         .         15         58.4         92         38-146         0.136           2         .37         46.0         50         18-83         .         .           90         73         44.9         92         38-146         0.136           2         .         .         .         .         .         .           91         .         .	Female	26	27.6	29	5-53	
Since in the second s						
y     94     46.2     44     14-4     0.439       N     7     51.4     .     .       PEDG PET     .     .     .       Y     57     46.5     50     26.74     0.296       N     54     41.9     30     9-51     0.296       PEDG SurMax (Cathegorical)     .     .     .     .       4/7     28     23.2     29     14-44     0.009       Tumor Size (Cathegorical)     .     .     .     . <j.j< td="">     58     55.7     65     39.91     0.104       &gt;3.3     58     55.7     65     39.91     0.104       &gt;3.3     51     58.4     92     38-146     0.136       P     1     51     58.4     92     38-146     0.136       2     37     46.0     50     18-83     3       3     15     39.2     33     8-58     4       4     8     14.6     13     11-15       PN     .     .     .     .     .       0     73     44.9     44     23-65     0.766       1     14     53.9     92     32-152     2</j.j<>	Smoking History		160			0.450
N       I       51.4       .       .         "FDG FFT       57       46.5       50       26.74       0.296         N       54       41.9       30       9.51       .         "FDG SuvMax (Cathegorical)       .       .       .       .       .         <9.7       34       65.5       .       .       .       .         >9.7       28       23.2       29       14.44       0.009         Tumor Size (Cathegorical)       .       .       .       .       .         <3.7       28       23.2       29       14.44       0.009         Tumor Size (Cathegorical)       .       .       .       .       . <d.3< td="">       53       39.5       33       10.56       0.104         &gt;J.J       51       58.4       92       38.146       0.136         2       37       46.0       50       18.43       3         3       15       39.2       33       8.58       1         4       8       16       13       11.15       15         pN       .       .       .       .       .         <td< th=""><th>Y</th><th>94</th><th>46.2</th><th>44</th><th>14-74</th><th>0.459</th></td<></d.3<>	Y	94	46.2	44	14-74	0.459
<sup>M</sup> FDG PET         Y         57         46.5         50         26.74         0.296           N         54         41.9         30         9.51 <sup>M</sup> FDG SurvMax (Cathegorical)               -9.7         28         23.2         29         14.44         0.009           Tumor Size (Cathegorical)               <3.3         58         55.7         65         39.91         0.104           >.3.3         53         75.7         65         39.91         0.104           >.3.3         53         75.7         65         39.91         0.104           >.3.3         53         75.7         65         39.91         0.104           >.3.3         53         73         30         15.5         15.33         11.5           pN                 g2         24         47.7         30              pN <td< th=""><th>N</th><th>7</th><th>51.4</th><th>•</th><th></th><th></th></td<>	N	7	51.4	•		
Proof VP I         Y         57         46.5         50         26.74         0.296           N         54         41.9         30         9.51         0.296           PFDG SuvMax (Cathegorical)         -         -         -         -         -           -9.7         28         23.2         29         1.4.40         0.009           Tumor Size (Cathegorical)         -         -         -         -         -           -3.3         53         39.5         33         10.56         0.104           >3.3         15         39.2         38.146         0.135           2         74.60         50         18.83         0.135           2         37         46.0         50         18.83           3         15         39.2         33         8.58           4         8         14.6         13         11.15           PN         -         -         -         -         -           0         73         44.9         44         23.65         0.766           1         14         53.9         92         32.152         -           2         24         47.7	18mm of more					
Y       57       46.5       50       26-74       0.295         MPDG SuvMax (Cathegorical)       54       41.9       30       9-51       0.009         *9.7       28       23.2       29       14.44       0.009         Tumor Size (Cathegorical)       -       -       -       -         <3.3       58       55.7       65       39-91       0.104         >3.3       53       39.5       33       10-56       0.104         pT       -       -       -       -       -       -         JT       51       58.4       92       38-146       0.136       -         pT       -       -       -       -       -       -       -         JT       51       58.4       92       38-146       0.136       -       -         JT       14       519       92       33       8-58       -       -       -         JN       -	"FDG PET		165	50	26.74	0.000
N       54       41.9       30       9-31         "FDG SuvMax (Cathegorical)	Y	5/	46.5	50	26-74	0.296
PFDG SuvMax (Cathegorical)         34         65.5         .         .           •9.7         28         23.2         29         14.44         0.009           Tumor Size (Cathegorical)         .         .         .         .           <3.3         58         55.7         65         39.91         0.104           >3.3         58         55.7         65         39.91         0.104           >3.3         58         55.7         65         39.91         0.104           >3.3         58         55.7         65         39.91         0.104           >3.3         10.56         18.83         0.136         18.83         11-15           PT         1         51         58.4         92         38.465         0.136           2         37         44.6         13         11-15         11         14         53.9         92         32-152         2           2         24         47.7         30         2         39.90         0.06           1/11/11/V         60         35.9         29         13-44.8         0024           N         37         61.0         71         38-104         0	N	54	41.9	30	9-51	
Proto Survivas (Cathegorical)         34         655         .         .           ≤9.7         28         23.2         29         14.44         0.009           Tumor Size (Cathegorical)         .         .         .         .           ≤3.3         58         55.7         65         39.91         0.104           >3.3         53         39.5         33         10-56           pT         .         .         .         .           I         51         58.4         92         38.146         0.136           2         37         46.0         50         18.83         3           3         15         39.2         33         8-58         4           4         8         14.6         13         11-15           pN         .         .         .         .         .           0         73         44.9         44         23.65         0.766           I         14         53.9         92         32.152         2           2         24         47.7         30         .         .           Immunoh Concol         .         .         . <t< th=""><th></th><th></th><th></th><th></th><th></th><th></th></t<>						
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	<sup>16</sup> FDG SuvMax (Cathegorical)	24				
>y.7       28       2.3.2       29       14-44       0.009         Tumor Size (Cathegorical)	<9.7	34	65.5			0.000
Tumor Size (Cathegorical)	>9.7	28	23.2	29	14-44	0.009
Intervise (Callegoreal)         58         55.7         65         39.91         0.104           >3.3         53         39.5         33         10.56						
23.3       58       55.7       65       39.91       0.104         >3.3       53       39.5       33       10.56         pT	Tumor Size (Cathegorical)	50		<i>(</i> <b>7</b>	20.01	0.104
S.J.     S.S.     S.S.     S.S.     S.S.     S.S.     10-56       PT     I     S1     S4.4     92     38-146     0.136       2     37     46.0     50     18.83     3       3     15     39.2     33     8-58       4     8     14.6     13     11-15       pN     0     73     44.9     44     23-65     0.766       I     14     S3.9     92     32-152     32-152       2     24     47.7     30     .       pStageGrouped     I     I     14     53.9     92     32-152       1     14     53.9     92     13-44.8     0.06       II-III-IV     60     35.9     29     13-44.8     0.06       Vascular Invasion^     I     S1     53.8     65     39-90     0.06       II-III-IV     60     35.9     29     13-44.8     0.024       N     37     61.0     71     38-104     0.024       N     37     61.0     71     38-104     0.691       >2/10HFF     18     45.6     43     .     0.691       >2/10HFF     93     44.9     40     <	<3.3	58	55.7	65	39-91	0.104
pT         I         51         58.4         92         38-146         0.136           2         37         46.0         50         18-83         13           3         15         39.2         33         8-58         4           4         16         13         11-15         11-15           pN         0         73         44.9         44         23-65         0.766           1         14         53.9         92         32-152         32         32         32         32         33         15         39.90         0.06         11         14         53.9         92         32-152         32         32         12         24         47.7         30         . <th>&gt;3.3</th> <th>53</th> <th>39.5</th> <th>33</th> <th>10-56</th> <th></th>	>3.3	53	39.5	33	10-56	
P1       51       58.4       92       38-146       0.136         2       37       46.0       50       18-83       3         3       15       39.2       33       8-58         4       8       14.6       13       11-15         pN						
I       51       58.4       92       38-146       0.156         2       37       46.0       50       18-83         3       15       39.2       33       8-58         4       8       14.6       13       11-15         pN $0$ 73       44.9       44       23-65       0.766         I       14       53.9       92       32-152 $0.066$ I       14       53.9       92       32-152 $0.066$ I       14       53.9       92       32-152 $0.066$ I       51       53.8       65       39-90 $0.066$ I-III-IV       60       35.9       29       13-44.8 $0.024$ Vascular Invasion^       Y       55       33.5       29       14-44 $0.024$ N       37       61.0       71       38-104 $0.691$ Vascular Invasion^       Y       55       33.5       29       14-44 $0.691$ Vascular Invasion^       Y       93       44.9       40       17-63         Necrosis       Y       90       43.2	pi	<b>51</b>	50.4	02	20.146	0.126
2       37       40.0       50       18-85         3       15       39.2       33       8-58         4       8       14.6       13       11-15         pN         0       73       44.9       44       23-65       0.766         I       14       53.9       92       32-152       32         2       24       47.7       30       .       .         PStageGrouped         I       51       53.8       65       39-90       0.06         II-III-IV       60       35.9       29       13-44.8       .         Vascular Invasion^       Y       55       33.5       29       14-44       0.024         N       37       61.0       71       38-104       .       .       .       .         Mitosis Number           .	1	51	58.4	92	38-146	0.136
3       15       39.2       35       8-58         4       8       14.6       13       11-15         pN $0$ 73       44.9       44       23-65       0.766         I       14       53.9       92       32-152 $2$ 2       24       47.7       30 $$	2	3/	46.0	50	18-83	
A       8       14.6       13       11-15         pN       .       .       .         0       73       44.9       44       23-65       0.766         I       14       53.9       92       32-152       .         pStageGrouped       .       .       .       .         I       51       53.8       65       39-90       0.06         II-III-IV       60       35.9       29       13-44.8       .         Vascular Invasion^       .       .       .       .       .         Y       55       33.5       29       14-44       0.024         N       37       61.0       71       38-104       .         Mitosis Number       .       <	3	15	39.2	33	8-38	
pN         0         73         44.9         44         23-65         0.766           I         14         53.9         92         32-152         2           2         24         47.7         30         .           pStageGrouped         .         .         .         .           I         51         53.8         65         39-90         0.06           II-III-IV         60         35.9         29         13-44.8         .           Vascular Invasion^         .         .         .         .         .           Vascular Invasion^         .           <	4	8	14.6	13	11-15	
P.N         44.9         44         23-65         0.766           I         14         53.9         92         32-152           2         24         47.7         30         .           pStageGrouped         .         .         .           I         51         53.8         65         39-90         0.06           II-III-IV         60         35.9         29         13-44.8         .           Vascular Invasion^         .         .         .         .         .           Y         55         33.5         29         14-44         0.024           N         37         61.0         71         38-104         .           Mitosis Number         .         .         .         0.691           <2//OHPF         18         45.6         43         .         0.691           >2/IOHPF         18         45.6         43         .         0.691           >2/IOHPF         18         45.4         71         19-124         .           Necrosis         .         .         .         .         .         .           P         30         48.1         40	N					
0       73       44.9       44       23-03       0.760         I       14       53.9       92       32-152       32         2       24       47.7       30       .       .         pStageGrouped       .       .       .       .       .         I       51       53.8       65       39-90       0.06         II-III-IV       60       35.9       29       13-44.8         Vascular Invasion^       .       .       .       .         Y       55       33.5       29       14-44       0.024         N       37       61.0       71       38-104       .       .         Mitosis Number       .       .       .       .       .       .          .       .       .       .       .       .       .       .         N       37       61.0       71       38-104       .	pix	72	44.0	4.4	22.65	0.766
I       14       53.9       92 $32-132$ 2       24       47.7       30       .         pStageGrouped       .       .       .         I       51       53.8       65       39-90       0.06         II-III-IV       60       35.9       29       13-44.8         Vascular Invasion^       .       .       .         Y       55       33.5       29       14-44       0.024         N       37       61.0       71       38-104         Mitosis Number       .       .       .       .          2/10HPF       18       45.6       43       .       0.691         >2/10HPF       93       44.9       40       17-63       .         Necrosis       .       .       .       .       .       .         Y       90       43.2       40       21-59       0.496         N       21       54.4       71       19-124       .         ImmunohCD56^       .       .       .       .       .       .         ImmunohCD56^A       .       .       .       .       .       . </th <th>0</th> <th>13</th> <th>44.9 52.0</th> <th>44</th> <th>23-05</th> <th>0.700</th>	0	13	44.9 52.0	44	23-05	0.700
2       24       41.7       50       .         pStageGrouped         I       51       53.8       65       39-90       0.06         II-III-IV       60       35.9       29       13-44.8         Vascular Invasion^         Y       55       33.5       29       14-44       0.024         N       37       61.0       71       38-104         Mitosis Number       .       .       .       .          2/10HPF       18       45.6       43       .       0.691         >2/10HPF       93       44.9       40       17-63       .       .         ImmunohCD56^         P       30       48.1       40       0-83       0.880         N       4       37.5       24       0-58       .         ImmunohCD56^       .       .       .       .       .         P       30       48.1       40       0-83       0.880         N       4       37.5       24       0-58       .	1	14	55.9 47 7	92	32-132	
pStageGrouped         51         53.8         65         39-90         0.06           II-III-IV         60         35.9         29         13-44.8            Vascular Invasion^                Y         55         33.5         29         14-44         0.024           N         37         61.0         71         38-104           Mitosis Number                44.9         40         17-63             Necrosis                Y         90         43.2         40         21-59         0.496           N                Y         90         43.2         40         21-59         0.496           N                ImmunohCD56^                ImmunohCD56^/ <th>2</th> <th>24</th> <th>47.7</th> <th>30</th> <th>•</th> <th></th>	2	24	47.7	30	•	
Singersonped       51       53.8       65       39-90       0.06         I-III-IV       60       35.9       29       13-44.8         Vascular Invasion^       Vascular Invasion^       Vascular Invasion       Vascular Invasion         Y       55       33.5       29       14-44       0.024         N       37       61.0       71       38-104       0.691         Mitosis Number       Vascular Invasion       Vascular Invasion       Vascular Invasion       0.691         Vascular Invasion       37       61.0       71       38-104       0.691         Mitosis Number       Vascular Invasion       Vascular Invasion       Vascular Invasion       Vascular Invasion         Visit Sin Number       Vascular Invasion       Vascular Invasion       Vascular Invasion       Vascular Invasion         Vascular Invasion       93       44.9       40       17-63       Vascular Invasion         Vascular Invasion       90       43.2       40       21-59       0.496         N       21       54.4       71       19-124       24         ImmunohCD56^       Vascular Invasion       Vascular Invasion       Vascular Invasion       Vascular Invasion         Mascular Invasion <th>nStogo(nouned</th> <th></th> <th></th> <th></th> <th></th> <th></th>	nStogo(nouned					
I       51       53.5       65       59-90       0.00         II-III-IV       60       35.9       29       13.44.8         Vascular Invasion^       7       55       33.5       29       14.44       0.024         N       37       61.0       71       38-104       0.06         Mitosis Number		51	52.9	65	20.00	0.06
Nerrosis       y $30$ $3.3$ $29$ $13-44.8$ Necrosis       y $55$ $33.5$ $29$ $14.44$ $0.024$ Nitosis Number $37$ $61.0$ $71$ $38-104$ Mitosis Number $37$ $61.0$ $71$ $38-104$ Necrosis $13-44.9$ $40$ $21-59$ $0.496$ N $21$ $54.4$ $71$ $19-124$ ImmunohCD56^{^{^{^{^{^{^{^{^{^{^{^{^{^{^{^{^{^{^{		50	25.0	20	12 11 8	0.00
Vascular Invasion^         Y         55         33.5         29         14-44         0.024           N         37         61.0         71         38-104           Mitosis Number         .	11-111-1 V	00	33.9	29	15-44.0	
Y       55       33.5       29       14.44       0.024         N       37       61.0       71       38-104         Mitosis Number       .       .       .       .         <2//0HPF	Vacular Invasion^					
I       33       33.3       23       1444       0.024         N       37       61.0       71       38-104         Mitosis Number       .       .       0.691         <2//0HPF       18       45.6       43       .       0.691         >2/10HPF       93       44.9       40       17-63       .         Necrosis       .	V	55	33.5	20	14 44	0.024
N     57     61.0     71     30104       Mitosis Number     71     30104       <2/10HPF     18     45.6     43     .     0.691       >2/10HPF     93     44.9     40     17-63       Necrosis     71     71     90       N     21     54.4     71     19-124       ImmunohCD56^     71     90     48.1     40     0-83     0.880       N     4     37.5     24     0-58     0.58	N	37	61.0	71	38-10/	0.024
Mitosis Number       45.6       43       .       0.691         >2/10HPF       93       44.9       40       17-63         Necrosis       .	1	57	01.0	/1	36-104	
<2/10HPF       18       45.6       43       .       0.691         >2/10HPF       93       44.9       40       17-63         Necrosis       .       .       .       .         Y       90       43.2       40       21-59       0.496         N       21       54.4       71       19-124       .         ImmunohCD56^       .       .       .       .       .         N       30       48.1       40       0-83       0.880         N       4       37.5       24       0-58       .	Mitosis Number					
C2/1011 P       16       43.0       43       .       6.031         >2/10HPF       93       44.9       40       17-63         Necrosis       V       90       43.2       40       21-59       0.496         N       21       54.4       71       19-124       90       48.1       40       0-83       0.880         N       30       48.1       40       0-58       0.880         N       4       37.5       24       0-58	<2/10HPF	18	45.6	/3		0.691
Necrosis     Y     90     43.2     40     21-59     0.496       N     21     54.4     71     19-124       ImmunohCD56^     Y     30     48.1     40     0-83     0.880       N     4     37.5     24     0-58	<2/10HPF	93	44.9	40	17-63	0.091
Necrosis         90         43.2         40         21-59         0.496           N         21         54.4         71         19-124         19-124           ImmunohCD56^         30         48.1         40         0-83         0.880           N         4         37.5         24         0-58         1	~2/10111 I	25	11.7	-10	17 05	
Y       90       43.2       40       21-59       0.496         N       21       54.4       71       19-124         ImmunohCD56^       V       V       V       V       V         P       30       48.1       40       0-83       0.880         N       4       37.5       24       0-58       0.580	Necrosis					
N     21     54.4     71     19-124       ImmunohCD56^     P     30     48.1     40     0-83     0.880       N     4     37.5     24     0-58	V	90	43.2	40	21-59	0.496
ImmunohCD56^     30     48.1     40     0-83     0.880       N     4     37.5     24     0-58	N	21	54.4	71	19-124	0.490
ImmunohCD56^         P       30       48.1       40       0-83       0.880         N       4       37.5       24       0-58         ImmunohCgA^       ImmunohCgA^       ImmunohCgA^       ImmunohCgA^       ImmunohCgA^		21	51.1		., 127	
P         30         48.1         40         0-83         0.880           N         4         37.5         24         0-58           ImmunohCgA^	ImmunohCD56^					
N         4         37.5         24         0-58           ImmunohCgA^         ImmunohCgA^         ImmunohCgA	P	30	48.1	40	0-83	0.880
ImmunohCgA^	N	4	37.5	24	0-58	0.000
ImmunohCgA^			01.0		0.00	
	ImmunohCgA^					

Surgery for Large-Cell-Neuroendocrine-Carcinoma

Р	87	48.0	50	19-81	0.352
Ν	12	18.8	31	17-45	
ImmunohSynaptop^					
Р	15	54.2			0.529
Ν	7	21.4	24	9-39	
ImmunohTTF1^					
Р	61	51.0	65	39-91	0.079
Ν	29	36.2	29	0-62	
Ki67^					
<50%	40	45.0	43	0-81	0.461
>50%	62	52.9			
(Neo)Chemotherapy					
Y	72	41.7	31	12-50	0.392
Ν	39	49.7	50	22-78	
Radiotherapy					
Y	22	47.0	31		0.755
N	89	45.2	43	16-70	

^ data missing

# Discussion

In this study, we observed that surgical resection may allow relatively favorable survivals (5yrs-OS=44.6%) in selected LCNEC patients. Independently from the choice of adjuvant chemotherapy regimen, when indicated, it corroborates results of most surgical teams showing 5-year survivals around 50%, in completely resected patients. Interestingly, we showed that FDG-uptake was the only factor independently predicting overall-survival. What is most striking here is the high prognostic value of tumor radiometabolic assessment at <sup>18</sup>F-FDG-PET/CT-scan (hazardratio=3.01) which was statistically stronger than usually reported factors such as p-stage, age, nodal status or type of adjuvant treatment [11, 12]. Although PET-CT is well known as diagnostic tool for predicting the histopathological nature of pulmonary lesions and differentiating benign or low-grade from intermediate or high-grade tumors, its prognostic impact within a specific subtype of NETs was rarely described [13]. Herein we observed a direct correlation between FDG-uptake and Ki67 expression and presence of necrosis; on the other hand the number of mitoses and the presence of vascular emboli did not influence the FDG uptake in our cohort of LCNEC patients. Therefore, we can hypothesize that <sup>18</sup>F-FDG-PET/CT allows a proper evaluation of disease biological behavior and substantially reflects processes likely involved in cells proliferation, metastatic potential, sensitivity to systemic treatments, and/or anticancer adaptive immunity. In fact, radiometabolic features of at PET-CT evaluation have been previously associated with PD-L1 expression of LCNECs, which also represents a key biomarker for predicting aggressiveness and response to treatments of NSCLCs, above all in the era of immune check-point inhibitors (ICIs) [14, 15].

Another debated issue of LCNEC multimodal management is the relevance, efficacy, and type of adjuvant chemotherapy. In metastatic and non-resectable LCNECs, numerous molecular targets were investigated for developing systemic therapies [16]. In locally treated

LCNEC patients, the choice of adjuvant regimen is, most of the time, binary and performed in analogy to NSCLC or SCLC according to pathological analysis of resected specimen and medical team policy. In our study, we failed to evidence any significant benefit of (neo)adjuvant chemotherapy in term of survival, probably because of the relatively small number of patients but this may also result from a too standardized, and non-customized, administrated regimen, which could theoretically be performed thanks to the analysis of "large" surgical specimens. Besides its above-discussed contribution in the setting of an increasing interest for ICI treatment of LCNECs, <sup>18</sup>F-FDG-PET/CT might be useful in choosing the appropriate adjuvant therapy.

# Conclusion

<sup>18</sup>F-FDG-PET/CT represents a relevant predictive factor of pathological features as well as long-term survival in a selected subset of LCNECs patients. While it stays as an efficient tool for eligibility to surgical resection, further analyses are needed to evaluate its usefulness in the choice of adjuvant or systemic treatments including immunotherapies.

# Acknowledgement

None

# **Conflicts of interest**

None declared

#### Funding

None

# REFERENCES

- Scoazec JY (2019) Lung and digestive neuroendocrine neoplasms. From WHO classification to biomarker screening: Which perspectives? Ann Endocrinol (Paris) 80: 163-165. [Crossref]
- Fournel L, Falcoz PE, Alifano M, Charpentier MC, Boudaya MS et al. (2013) Surgical management of pulmonary large cell neuroendocrine carcinomas: a 10-year experience. *Eur J Cardiothorac Surg* 43: 111-114. [Crossref]
- Kim KW, Kim HK, Kim J, Shim YM, Ahn MJ et al. (2017) Outcomes of Curative-Intent Surgery and Adjuvant Treatment for Pulmonary Large Cell Neuroendocrine Carcinoma. *World J Surg* 41: 1820-1827. [Crossref]
- Rieber J, Schmitt J, Warth A, Muley T, Kappes J, Eichhorn F et al. (2015) Outcome and prognostic factors of multimodal therapy for pulmonary large-cell neuroendocrine carcinomas. *Eur J Med Res* 20: 64. [Crossref]
- Grand B, Cazes A, Mordant P, Foucault C, Dujon A et al. (2013) High grade neuroendocrine lung tumors: pathological characteristics, surgical management and prognostic implications. *Lung Cancer* 81: 404-409. [Crossref]
- Makino T, Mikami T, Hata Y, Otsuka H, Koezuka S et al. (2016) Comprehensive Biomarkers for Personalized Treatment in Pulmonary Large Cell Neuroendocrine Carcinoma: A Comparative Analysis with Adenocarcinoma. *Ann Thorac Surg* 102: 1694-1701. [Crossref]
- Derks J, van Suylen RJ, Thunnissen E, den Bakker M, Groen H et al. (2017) Why we should improve current practice of diagnosing and treating pulmonary large cell neuroendocrine carcinomas in patients with advanced disease. *Eur Respir J* 50. [Crossref]
- Lococo F, Galeone C, Formisano D, Bellafiore S, Filice A et al. (2017) 18F-fluorodeoxyglucose positron emission tomographic scan in solidtype p-stage-I pulmonary adenocarcinomas: what can produce falsenegative results? *Eur J Cardiothorac Surg* 51: 667-673. [Crossref]

- Rami-Porta R, Wittekind C, Goldstraw P (2005) Complete resection in lung cancer surgery: proposed definition. *Lung Cancer* 49: 25-33. [Crossref]
- Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG (2015) World Health Organization, International Agency for Research on Cancer, International Association for the Study of Lung Cancer, International Academy of Pathology. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press.
- Filosso PL, Rena O, Guerrera F, Moreno Casado P, Sagan D et al. (2015) Clinical management of atypical carcinoid and large-cell neuroendocrine carcinoma: a multicentre study on behalf of the European Association of Thoracic Surgeons (ESTS) Neuroendocrine Tumours of the Lung Working Group<sup>†</sup>. *Eur J Cardiothorac Surg* 48: 55-64. [Crossref]
- Hermans BCM, Derks JL, Thunnissen E, van Suylen RJ, den Bakker MA et al. (2019) Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC). Lung Cancer 130: 179-186. [Crossref]
- Lococo F, Cesario A, Paci M, Filice A, Versari A et al. (2014) PET/CT assessment of neuroendocrine tumors of the lung with special emphasis on bronchial carcinoids. *Tumour Biol* 35: 8369-8377. [Crossref]
- Takada K, Toyokawa G, Okamoto T, Baba S, Kozuma Y et al. (2017) Metabolic characteristics of programmed cell death-ligand 1expressing lung cancer on 18 F-fluorodeoxyglucose positron emission tomography/computed tomography. *Cancer Med* 6: 2552-2561. [Crossref]
- Kim HS, Lee JH, Nam SJ, Ock CY, Moon JW et al. (2018) Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung. J Thorac Oncol 13: 636-648. [Crossref]
- Tsoukalas N, Baxevanos P, Aravantinou-Fatorou E, Tolia M, Galanopoulos M et al. (2018) Advances on systemic treatment for lung neuroendocrine neoplasms. *Ann Transl Med* 6: 146. [Crossref]